###begin article-title 0
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 136 162 136 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT-motif binding factor 1 </italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1</italic>
###xml 170 172 170 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 449 457 449 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 573 581 573 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 775 783 775 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Loss of heterozygosity (LOH) on the long arm of chromosome 16 is one of the most frequent genetic events in solid tumors. Recently, the AT-motif binding factor 1 (ATBF1)-A gene, which has been assigned to chromosome 16q22.3-23.1, was identified as a plausible candidate for tumor suppression in solid tumors due to its functional inhibition of cell proliferation and high mutation rate in prostate cancer. We previously reported that a reduction in ATBF1-A mRNA levels correlated with a worse prognosis in breast cancer. However, the mechanisms regulating the reduction of ATBF1-A mRNA levels (such as mutation, methylation in the promoter region, or deletion spanning the coding region) have not been fully examined. In addition, few studies have analyzed LOH status at the ATBF1-A locus, located in the 16q22 minimal region.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Profiles of ATBF1-A mRNA levels that we previously reported for 127 cases were used. In this study, breast cancer specimens as well as autologous blood samples were screened for LOH using 6 polymorphic microsatellite markers spanning chromosome band 16q22. For mutational analysis, we selected 12 cases and analyzed selected spots in the ATBF1-A coding region at which mutations have been frequently reported in prostate cancer.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 138 146 138 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 307 315 307 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 358 366 358 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Forty-three cases that yielded clear profiles of LOH status at both D16S3106 and D16S3018 microsatellites, nearest to the location of the ATBF1-A gene, were regarded as informative and were classified into two groups: LOH (22 cases) and retention of heterozygosity (21 cases). Comparative assessment of the ATBF1-A mRNA levels according to LOH status at the ATBF1-A locus demonstrated no relationship between them. In the 12 cases screened for mutational analysis, there were no somatic mutations with amino acid substitution or frameshift; however, two germ line alterations with possible polymorphisms were observed.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
These findings imply that ATBF1-A mRNA levels are regulated at the transcriptional stage, but not by genetic mechanisms, deletions (LOH), or mutations.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 323 334 323 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E-cadherin </italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 448 474 448 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT-motif binding factor 1 </italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1</italic>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Previous studies, including ours, have shown that loss of heterozygosity (LOH) on the long arm of chromosome 16 is one of the most frequent genetic events in breast, gastric and prostate cancers, implying the presence of one or more tumor suppressor genes (TSGs) at this location [1-7]. In breast cancer, the gene encoding E-cadherin at 16q22.1 was identified as a TSG, but only in the histological subgroup of lobular carcinoma [8]. Recently, the AT-motif binding factor 1 (ATBF1)-A gene (GenBank: ), which has been assigned to chromosome 16q22.3-23.1 [9], was identified as a reasonable candidate for tumor suppressor activity in solid tumors, based on its functional inhibition of cell proliferation and high rate of mutations in prostate cancer [10].
###end p 11
###begin p 12
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 79 97 79 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">alpha-fetoprotein </italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 216 224 216 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 349 357 349 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN1A </italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 477 485 477 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
ATBF1-A was originally identified as a negative transcriptional factor for the alpha-fetoprotein (AFP) gene through binding with the AT-rich motif in the AFP enhancer element I [11,12]. In gastric cancer, absence of ATBF1-A is a distinct feature of AFP-producing cancer cells, which are characterized by a high malignant potential [7,13]. Moreover, ATBF1-A negatively regulates the c-Myb oncoprotein [14] and transactivates the cell cycle inhibitor CDKN1A [15]. Therefore, the ATBF1-A gene is considered to be a good TSG candidate in solid tumors.
###end p 12
###begin p 13
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 209 211 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 259 267 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 308 310 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 334 342 330 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 441 443 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 484 492 480 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Previously, we reported that reduced ATBF1-A mRNA levels in tumors correlated with axillary lymph node metastasis and estrogen receptor (ER)-alpha negative status in breast cancer, and with a worse prognosis [16]. Sun et al. confirmed the presence of reduced ATBF1-A mRNA levels in breast cancer cell lines [17]. However, the reduced ATBF1-A mRNA expression was attributed neither to promoter methylations nor to frequent somatic mutations [17]. Therefore, the authors concluded that ATBF1-A plays a role in breast cancer through transcriptional down-regulation rather than promoter methylation or mutations.
###end p 13
###begin p 14
###xml 265 273 265 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 316 324 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AFBF1-A </italic>
###xml 531 539 531 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 629 637 629 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 755 763 755 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
In addition to promoter methylations or mutations, LOH resulting from a deletion spanning one or more genes is one of the mechanisms by which the function of genes is lost. However, there are no papers in which has been reported the associations between LOH at the ATBF1-A locus [10] in the 16q22 minimal region and AFBF1-A mRNA levels, or between LOH at this locus and the clinicopathological factors in breast cancer. We performed LOH analysis at the 16q22 minimal region and mutational analysis focusing on specific loci in the ATBF1-A gene, which have been reported previously in prostate cancer[10]. Our analysis shows that ATBF1-A mRNA levels are not regulated by genetic machinery, LOH, or mutations. These findings could support the view that the ATBF1-A gene plays a role in breast cancer through transcriptional down-regulation rather than through LOH and mutations.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 16
###begin p 17
###xml 286 294 286 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1155 1157 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1479 1481 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
###xml 764 772 <span type="species:ncbi:9606">patients</span>
###xml 812 820 <span type="species:ncbi:9606">patients</span>
###xml 1030 1038 <span type="species:ncbi:9606">Patients</span>
###xml 1200 1207 <span type="species:ncbi:9606">patient</span>
Specimens of primary breast carcinomas were obtained by surgical excision from 127 female patients who received treatment at the Department of Breast and Endocrine Surgery, Nagoya City University Hospital, Nagoya, Japan, between 1993 and 2000. All the patients in the present study had ATBF1-A mRNA profiles, as reported previously [16]. Informed consent was obtained from all the patients before surgery. The ethics committee of Nagoya City University Graduate School of Medicine, Nagoya, approved the study protocol. Of the 127 tumors obtained from these patients, 109 were infiltrating ductal carcinomas and 14 were special type carcinomas, including 8 infiltrating lobular carcinomas. The remaining 4 patients had noninvasive carcinomas. The median age of the patients was 58 years (range, 34-88 years). The patients' tumors were classified according to the staging system of International Union Against Cancer as follows: 4 cases were classified as stage 0, 29 as stage I, 78 as stage II, 12 as stage III, and 4 as stage IV. Patients were graded histopathologically according to the modified Bloom and Richardson method proposed by Elston and Ellis [18]. Blood samples were also taken from each patient. Genomic DNA from the breast cancer specimens and blood samples were extracted by standard techniques. Breast cancer specimens were verified not to contaminate normal cells at 10% or more of each sample on the hematoxylin and eosin stained slides as previously described[19].
###end p 17
###begin title 18
Microsatellite markers and LOH analysis
###end title 18
###begin p 19
###xml 171 179 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1182 1183 1130 1131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1559 1560 1504 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
The breast cancer specimens as well as the autologous blood samples were screened using 6 polymorphic microsatellite markers spanning chromosome band 16q22 containing the ATBF1-A gene. The order of microsatellite loci was assessed as reported by Sun et al[10] and with reference to NCBI [20]. Details of the investigated markers and their chromosomal locations are provided in Table 1. Assays were performed by fluorescent-labeled PCR amplification using fluorescent dye-labeled forward primer and unlabeled reverse primer (Applied Biosystems). PCR was performed in 15-muL reaction volumes containing 120 ng of genomic DNA, 9 muL of ABI Prism True Allele PCR Premix (Applied Biosystems), 5 pmol of fluorescent dye-labeled forward primer, and 5 pmol of unlabeled reverse primer under the following cycling conditions recommended by manufacture's instructions: denaturation at 95degreesC for 12 min; 10 cycles at 94degreesC for 15 s, 55degreesC for 15 s, and 72degreesC for 30 s; 20 cycles at 89degreesC for 15 s, 55degreesC for 15 s, and 72degreesC for 30 s; and a final extension at 72degreesC for 10 min. Each 1-muL sample of the resulting PCR products was diluted with 20 muL of H2O, and a 1.0-muL aliquot of each diluted fluorescent-labeled PCR product was combined with 12 muL of formamide and 0.5 muL of GeneScan 500 LIZ size standard (Applied Biosystems). Capillary electrophoresis was then performed using an ABI 310 DNA Analyzer, and the results were analyzed using GeneMapper software (Applied Biosystems). Representative results are shown in Figure 1. Allelic loss at each microsatellite locus was considered to be present in tumor samples' DNA when there was at least a 65% peak reduction at one of a pair peak compared with the corresponding peak of normal DNA.
###end p 19
###begin p 20
Characteristics of polymorphic loci at the 16q22 minimal region
###end p 20
###begin p 21
The genetic maps were cited from NCBI Map Viewer . ND, not described.
###end p 21
###begin p 22
###xml 0 121 0 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative examples of microsatellite analysis for D16S3018 in breast cancer patients with paired tumor-blood samples</bold>
###xml 123 127 123 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 200 204 200 204 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 233 237 233 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Representative examples of microsatellite analysis for D16S3018 in breast cancer patients with paired tumor-blood samples. (a) Loss of heterozygosity at D16S3018. The arrow indicates the allele loss. (b) Retention of heterozygosity. (c) Uninformative sample due to the homozygosity at D16S3018. Each peak has a box that provides the fragment size and peak height (upper and lower labels, respectively).
###end p 22
###begin title 23
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Gene alterationanalysis of ATBF1-A gene
###end title 23
###begin p 24
###xml 23 31 23 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 361 369 361 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
With intent to analyze ATBF1-A mutations, we selected all the mutational spots in exon 9 and the most frequent deletion spot in exon 10 reported in prostate cancer because > 80% of the mutations reported in the paper were located in these spots (Table 2) [10]. Genomic DNA was amplified by PCR using the amplifying and sequencing primers for these spots on the ATBF1-A gene, as listed in Table 2. For mutation identification, the samples were subsequently analyzed using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). The sequencings from 50 to 250 bp, counting from the starting point, were regarded as the region of interest.
###end p 24
###begin p 25
Paired primers used to amplify the specific sequence of ATBF1-A, including the partial mutation loci previously reported in prostate cancer
###end p 25
###begin p 26
###xml 1 7 1 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1 </italic>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
*ATBF1 mutations previously reported in prostate cancer by Sun et al. [10]
###end p 26
###begin title 27
###xml 69 74 <span type="species:ncbi:9606">human</span>
Immunohistochemical staining of ER-alpha, progesterone receptor, and human epidermal growth factor receptor 2
###end title 27
###begin p 28
###xml 148 150 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 757 759 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 840 842 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 378 384 <span type="species:ncbi:9986">rabbit</span>
Immunostaining of ER-alpha, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) was performed, as described previously [21]. Primary antibodies included monoclonal mouse antihuman estrogen receptor antibody (1D5; DAKO, Glostrup, Denmark) at 1:100 dilution for ER-alpha, antihuman PR antibody (PR636; DAKO, Kyoto, Japan) at 1:100 dilution for PR, and rabbit antihuman c-erbB2 oncoprotein antibody (DAKO) at 1:200 dilution for HER2. A Streptavidin-biotin system (SAB-PO kit; Nichirei, Tokyo, Japan) was used for the detection of ER-alpha, PR, and HER2 according to the manufacturer's instructions. The expression of ER-alpha and PR was scored by assigning a proportion score and an intensity score according to Allred's procedure [22]. Immunohistochemical scoring of HER2 was accomplished as described previously [21].
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 117 125 117 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 135 143 135 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 163 165 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 208 216 206 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 284 286 282 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The nonparametric Mann-Whitney U-test was used for statistical analysis of the association between LOH status at the ATBF1-A locus and ATBF1-A mRNA levels. The chi2 test was used to compare LOH status at the ATBF1-A locus with the clinicopathological characteristics. All values with P < 0.05 were considered statistically significant.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
Loss of heterozygosity at chromosome band 16q22
###end title 32
###begin p 33
###xml 178 186 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 611 619 611 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 779 787 779 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 1078 1086 1078 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 1134 1142 1134 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 1432 1433 1432 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1714 1722 1714 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 1732 1740 1732 1740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Initially, we performed LOH analysis using microsatellite markers spanning 16q22. Sun et al. narrowed the region of deletion at 16q22 in prostate cancer to 861 kb containing the ATBF1-A gene[10]. We used microsatellite markers either in the narrowed 861-kb region or close to the narrowed region spanning 16q22 (Table 1). However, both microsatellite markers in the narrowed region, RH69880 and D16S2859, were homozygous (uninformative). Thereafter, we performed LOH mapping using 6 other microsatellite markers. Next, to determine the most reasonable set of microsatellite markers reflecting LOH status at the ATBF1-A locus, we tested various kinds of microsatellite marker sets from among the 6 microsatellite markers (data not shown). Ultimately, we defined LOH status at the ATBF1-A locus as follows: LOH was identified when the microsatellite markers at both D16S3106 and D16S3018 showed LOH; retention of heterozygosity (ROH), when both D16S3106 and D16S3018 showed ROH; not determined (ND), when there was discrepancy in LOH status between D16S3106 and D16S3018, because ATBF1-A is located between these markers, LOH status at ATBF1-A is not rigorously determined in this case; and uninformative (UI), when there was constitutional homozygosity or an uninterpretable result for at least one of the two microsatellites. The partial results (all cases except UI) of LOH analysis at the 16q22 minimal region are shown in Figure 2. Constitutional heterozygous (informative) status in both D16S3106 and D16S3018 was observed in 52 cases (44.4%). Of the 52 cases, clear LOH was seen in 22 cases (42.3%), ROH in 21 (40.4%), and ND in 9 (17.3%). Subsequently, we analyzed the relationship between LOH status at the ATBF1-A locus and ATBF1-A mRNA expression levels as well as the clinicopathological factors in a study cohort consisting of these 43 informative cases, classifying them into LOH (n = 22) and ROH (n = 21) groups.
###end p 33
###begin p 34
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Loss of heterozygosity (LOH) mapping of the 16q22 minimal region in breast cancer</bold>
###xml 163 171 163 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Loss of heterozygosity (LOH) mapping of the 16q22 minimal region in breast cancer. All cases except those that were uninformative are shown. The LOH status at the ATBF1-A gene locus was categorized as follows: LOH, indicating that LOH status at both D16S3106 and D16S3018 showed LOH; retention of heterozygosity (ROH), indicating that both D16S3106 and D16S3018 showed ROH; not determined, indicating that there was a discrepancy in LOH status between D16S3106 and D16S3018.
###end p 34
###begin title 35
###xml 67 75 67 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Comparison of ATBF1 mRNA expression according to LOH status at the ATBF1-A locus
###end title 35
###begin p 36
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF-A </italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 199 207 199 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 239 247 239 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 329 337 329 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 444 452 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 499 507 499 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 680 688 680 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
In a previous study, we demonstrated that the ATBF-A mRNA expression level was a significant prognostic marker in breast cancer [16]. However, the factors regulating the transcriptional level of the ATBF1-A gene are still not clear. Using ATBF1-A mRNA data, as reported previously [16], we investigated whether LOH status at the ATBF1-A locus regulates the transcriptional level of the ATBF1-A gene. Figure 3 shows a quantitative assessment of ATBF1-A mRNA expression according to LOH status at the ATBF1-A locus and demonstrates that there was no relationship between them. This finding indicates that another mechanism is involved in regulating the transcriptional level of the ATBF1-A gene.
###end p 36
###begin p 37
###xml 90 98 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of ATBF1-A mRNA levels according to loss of heterozygosity (LOH) status at the <italic>ATBF1-A </italic>locus</bold>
###xml 150 158 150 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 192 200 192 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 207 209 207 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Comparison of ATBF1-A mRNA levels according to loss of heterozygosity (LOH) status at the ATBF1-A locus. There was no significant correlation between ATBF1-A mRNA levels and LOH status at the ATBF1-A locus (P = 0.101). ROH, retention of heterozygosity.
###end p 37
###begin title 38
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
ATBF1-A nucleotide alterations in breast cancer
###end title 38
###begin p 39
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 77 85 77 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 362 370 362 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 496 504 496 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 525 533 525 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 1054 1056 1054 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1152 1154 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1501 1503 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 765 773 <span type="species:ncbi:9606">patients</span>
###xml 943 950 <span type="species:ncbi:9606">patient</span>
We next performed mutational analysis of the ATBF1-A gene to inspect whether ATBF1-A mRNA expression levels could be related with mutations succeeding to the instabilities of their transcripts. We selected all the mutational spots located in exon 9 and the most frequent deletion spot in exon 10 (Table 2), because > 80% of the mutations in the coding region of ATBF1-A gene reported in prostate cancer occurred in these locations. Twelve patients with tumors that did not demonstrate LOH at the ATBF1-A locus but with lower ATBF1-A mRNA expression were chosen as study subjects for mutational analysis. Overall, five sequence alterations, including both mutations and polymorphism, were found in the abovementioned spots in the 12 samples from these patients. Two patients had a somatic (blood sample not matched) 5602C > T mutation in one allele that did not involve amino acid substitution (i.e., synonym mutations). On the other hand, one patient had a 5602C > T blood-sample matched alteration in one allele that was reported on the dbSNP database [23]. We therefore regarded it as a single nucleotide polymorphism (SNP), as reported by Sun et al[17]. Both the remaining samples demonstrated a germ line alteration (blood-sample matched) in one allele. One of them, 8387A > G, caused a substitution of methionine for valine at codon 2572. The other alteration was a deletion (10799-10804) without frameshift. Although both gene alterations were not reported in the NCBI dbSNP and JSNP databases [24], we could not immediately rule out the possibility that these alterations were benign polymorphisms.
###end p 39
###begin title 40
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Relationship between LOH status of the ATBF1-A locus and clinicopathological factors
###end title 40
###begin p 41
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 169 171 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 208 216 204 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 325 326 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 339 347 335 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 387 389 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 422 424 418 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 523 531 515 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 666 674 654 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 751 753 739 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 811 819 799 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 441 449 <span type="species:ncbi:9606">Patients</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
As the reduced ATBF1-A mRNA expression levels correlated with unfavorable characteristics of tumors, ER-alpha- negative and lymph node metastasis, in our previous study[16], we wondered whether LOH status at ATBF1-A locus were related with clinicopathological factors as well. The results of this analysis are shown in Table 3. LOH at the ATBF1-A locus correlated with positivity of PR (P = 0.013) and negativity of HER2 (P = 0.024) status. Patients with ER-alpha-positive tumors were more likely to demonstrate LOH at the ATBF1-A locus than those with ER-alpha-negative tumors; however, the difference was not significant. Furthermore, the patients with LOH at the ATBF1-A locus more often had axillary lymph node involvement than those without LOH (P = 0.084). No relationship was observed between LOH at the ATBF1-A locus and other clinicopathological factors, such as age, tumor size, and histological grade.
###end p 41
###begin p 42
Correlation between clinicopathological factors and the LOH status at the 16q22 minimal locus
###end p 42
###begin p 43
###xml 52 57 <span type="species:ncbi:9606">human</span>
Estrogen receptor-alpha, progesterone receptor, and human epidermal growth factor (HER) 2 were determined histochemically.
###end p 43
###begin p 44
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
*P < 0.05.
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 332 340 332 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 365 372 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A</italic>
###xml 462 470 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 517 525 517 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 817 825 817 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
Using polymorphic microsatellite markers spanning chromosome 16q22, we performed fluorescent-labeled PCR amplification and capillary electrophoresis to investigate LOH status at the 16q22 minimal region in paired specimens of blood and primary breast tumors from 127 patients. We assessed the relationship between LOH status at the ATBF1-A locus and mRNA levels of ATBF1-A, as well as the clinicopathological factors in breast cancer. Quantitative assessment of ATBF1-A mRNA expression according to LOH status at the ATBF1-A locus demonstrated no relationship between these factors. This finding completely consists with the result repoted by Kim et al., studied in hepatocellular carcinoma (HCC)[25]. We therefore concluded that a mechanism other than LOH was involved in regulating the transcriptional level of the ATBF1-A gene in breast cancer as like in HCC.
###end p 46
###begin p 47
###xml 63 71 63 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 250 258 250 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 296 304 296 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 764 765 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1144 1145 1144 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1146 1147 1146 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1148 1150 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1151 1153 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1330 1332 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1484 1485 1484 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Accordingly, we screened mutations of the specific loci in the ATBF1-A gene that have previously been reported in prostate cancer [10]. The 12 tumors investigated for mutations had been predicted to have a higher frequency of gene alterations in the ATBF1-A gene, because they demonstrated lower ATBF1-A mRNA levels but showed ROH at the ATBF1-A locus (data not shown). In the mutational analyses, although none of the 12 samples studied showed somatic mutations with substitution of amino acids or frameshift, two germ line gene alterations were recorded. One of these alterations predicted a substitution of methionine for valine at codon 2572. This alteration also reported in gastric cancer as a somatic mutation at one allele, while the other allele had lost[7]. Although the gene alteration was not reported in the NCBI SNP and JSNP databases, pathogenic significance of the gene alteration was also not verified by functional assay. The remaining gene alteration produced a 6-nucleotide deletion without frameshift in glutamic acid rich domain in exon10. Although the 3 - 24 nucleotides deletions are prevalent in various kind of tumors[6,7,10,26], its pathogeny is controversial among those tumors. In prostate cancer, Xu et. reported the deletions in germline and its relevance with the susceptibility to prostate cancer[26]. Contrast to that, in breast cancer, Cleton-Jansen et al. reported no association between these germline deletions and suscetability to breast cancer[6]. This indicate that these germline deletions has different impacts in the suscetabilities to these tumors. As in the present study, the deletion was also germline, they might be benign polymorphisms regarding with the susceptibility to breast cancer.
###end p 47
###begin p 48
###xml 345 353 345 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 537 545 537 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 692 693 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 770 776 770 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1 </italic>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 832 834 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
A larger case-control study compared between cancer patients and healthy individuals and functional analysis in each gene alteration should be performed to reveal their pathogenic significances in tumorigenesis. As, consequently, somatic mutations with substitution of amino acids or frameshift were not seen in these samples, we concluded that ATBF1-A mRNA levels may be regulated at the transcriptional stage, but are not regulated by genetic mechanisms, deletions (LOH), or mutations in breast cancer. Infrequent somatic mutations in ATBF1-A gene have previously been reported, except for prostate cancer. The frequencies were 8.6% in gastric cancer[7], 0% in HCC[25], 0% in breast cancer[6]. In addition, Sun et al. and Kim et al. reported infrequent methylation at ATBF1 gene promoter in breast cancer and HCC, respectively[17,25]. Based on these reports, we speculate that the methylations at ATBF1-A gene are also not attributed to the downregulation of ATBF1-A transcripts, though we did not performed the methylation analysis.
###end p 48
###begin p 49
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 494 502 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 585 593 585 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 603 611 603 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
Recently, posttranscriptional mRNA repression associated with microRNA (miRNA) have been discussed as an alternative mechanism of mRNA modulation at the posttranscriptional level in mammals as well as metazoa [27]. According to the prevailing model, posttranscriptional repression by miRNA is determined by the complementarity to the miRNA of the target mRNA[27]. Therefore, we may speculate that posttranscriptional cleavage of mRNA by miRNA-associated machinery is the molecular mechanism of ATBF1-A mRNA regulation. This may explain why there is a discrepancy between LOH status at ATBF1-A locus and ATBF1-A mRNA levels.
###end p 49
###begin p 50
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 80 82 80 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 115 117 115 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 447 449 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 480 482 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 704 706 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
LOH status at the ATBF1-A locus significantly correlated with positivity of PR (P = 0.013) and negativity of HER2 (P = 0.024) status. Similar results were previously reported by Wang [28], who found that 16q23-24 genetic loss significantly correlated with ER-alpha positivity and HER2 negativity. These biological features, hormonal receptor positivity, and HER2 negativity, are reminiscent of the "luminal-type" tumors described by Perou et al. [29]. Based on the study by Wang [28] and the present study, a target gene at the narrowed locus spanning from 16q22 to 16q24 may determine the biological features of the luminal-type. Recent cytogenetic approaches, such as comparative genomic hybridization[30], may help reveal the new target gene at this locus in such cohorts.
###end p 50
###begin title 51
Conclusion
###end title 51
###begin p 52
###xml 102 110 102 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 256 264 256 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 274 282 274 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 588 596 588 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A </italic>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
Using polymorphic microsatellite markers spanning chromosome band 16q22, we defined LOH status at the ATBF1-A locus and performed comparative analysis between LOH and ROH groups. However, we did not find a significant correlation between LOH status at the ATBF1-A locus and ATBF1-A mRNA levels. Furthermore, we found no somatic mutations with amino acid substitution in 12 tumor samples from selected patients who were predicted to have a higher frequency of gene alterations, although two germ line alterations with the possibility of polymorphism were noted. We therefore conclude that ATBF1-A mRNA levels may be regulated at the transcriptional stage.
###end p 52
###begin title 53
Abbreviations
###end title 53
###begin p 54
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATBF1-A</italic>
LOH: loss of heterozygosity; ATBF1-A: AT-motif binding factor 1-A; TSG: tumor suppressor gene; AFP: alpha-fetoprotein; ROH: retention of heterozygosity; ND: not determined; UI: uninformative; SNP: single nucleotide polymorphism; miRNA: microRNA
###end p 54
###begin title 55
Competing interests
###end title 55
###begin p 56
The authors declare that they have no competing interests.
###end p 56
###begin title 57
Authors' contributions
###end title 57
###begin p 58
K.K. performed the molecular genetic studies, participated in the LOH analysis and sequence alignment, and drafted the manuscript. Z.Z. performed the sequence alignment and scored the status of immunohistochemical staining. H.Y. was involved in the study design and scored the status of immunohistochemical staining. Y.M. was involved in the study design and assisted in drafting of the manuscript. Y.Y. and H.I. conceived the study, participated in its design and coordination, and assisted in drafting of the manuscript. All authors have read and approved the final manuscript.
###end p 58
###begin title 59
Pre-publication history
###end title 59
###begin p 60
The pre-publication history for this paper can be accessed here:
###end p 60
###begin p 61

###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
We thank Dr. Yoshitaka Fujii, the Department of Surgery II, Nagoya City University Medical School, for his comprehensive advice on the study, Dr. Ando Takuya for technical advice, and Ms. Mariko Nishio for technical support.
###end p 63
###begin article-title 64
Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast
###end article-title 64
###begin article-title 65
###xml 26 31 <span type="species:ncbi:9606">human</span>
DNA copy number losses in human neoplasms
###end article-title 65
###begin article-title 66
Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type
###end article-title 66
###begin article-title 67
Genetic alterations in breast cancer
###end article-title 67
###begin article-title 68
Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions
###end article-title 68
###begin article-title 69
ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism
###end article-title 69
###begin article-title 70
Genetic alterations of the ATBF1 gene in gastric cancer
###end article-title 70
###begin article-title 71
###xml 59 64 <span type="species:ncbi:9606">human</span>
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers
###end article-title 71
###begin article-title 72
###xml 18 23 <span type="species:ncbi:9606">human</span>
Assignment of the human ATBF1 transcription factor gene to chromosome 16q22.3-q23.1
###end article-title 72
###begin article-title 73
###xml 64 69 <span type="species:ncbi:9606">human</span>
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer
###end article-title 73
###begin article-title 74
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human alpha-fetoprotein enhancer-binding protein, ATBF1, contains four homeodomains and seventeen zinc fingers
###end article-title 74
###begin article-title 75
###xml 102 107 <span type="species:ncbi:9606">human</span>
ATBF1, a multiple-homeodomain zinc finger protein, selectively down-regulates AT-rich elements of the human alpha-fetoprotein gene
###end article-title 75
###begin article-title 76
Alpha-fetoprotein producing gastric cancer lacks transcription factor ATBF1
###end article-title 76
###begin article-title 77
Myb-interacting protein, ATBF1, represses transcriptional activity of Myb oncoprotein
###end article-title 77
###begin article-title 78
ING1 represses transcription by direct DNA binding and through effects on p53
###end article-title 78
###begin article-title 79
ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer
###end article-title 79
###begin article-title 80
###xml 32 37 <span type="species:ncbi:9606">human</span>
Infrequent mutation of ATBF1 in human breast cancer
###end article-title 80
###begin article-title 81
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
###end article-title 81
###begin article-title 82
Low Frequency Loss of Heterozygosity in the BRCA1 Region in Japanese Sporadic Breast Cancer
###end article-title 82
###begin article-title 83
NCBI Map Viewer
###end article-title 83
###begin article-title 84
Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast
###end article-title 84
###begin article-title 85
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
###end article-title 85
###begin article-title 86
dbSNP database
###end article-title 86
###begin article-title 87
A database of Japanese Single Nucleotide Polymorphisms
###end article-title 87
###begin article-title 88
Down-regulation of ATBF1 is a major inactivating mechanism in hepatocellular carcinoma
###end article-title 88
###begin article-title 89
Germline ATBF1 mutations and prostate cancer risk
###end article-title 89
###begin article-title 90
MicroRNAs: genomics, biogenesis, mechanism, and function
###end article-title 90
###begin article-title 91
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers
###end article-title 91
###begin article-title 92
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 92
###begin article-title 93
Array-CGH and breast cancer
###end article-title 93

